Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker EIKN
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Oct 7, 2026 | SCHEDULE 13G/A (amended) | EIKN Eikon Therapeutics, Inc. | Abigail P. Johnson | 5.52M | 10.2% | SCHEDULE 13G/A ↗ |
| Oct 7, 2026 | SCHEDULE 13G/A (amended) | EIKN Eikon Therapeutics, Inc. | FMR LLC | 5.52M | 10.2% | SCHEDULE 13G/A ↗ |
| Oct 2, 2026 | SCHEDULE 13G/A (amended) | EIKN Eikon Therapeutics, Inc. | Platinum Falcon B 2018 RSC Limited | 1.15M | 2.1% | SCHEDULE 13G/A ↗ |
| Oct 2, 2026 | SCHEDULE 13G/A (amended) | EIKN Eikon Therapeutics, Inc. | Abu Dhabi Investment Authority | 1.15M | 2.1% | SCHEDULE 13G/A ↗ |
| Aug 6, 2026 | SCHEDULE 13G/A (amended) | EIKN Eikon Therapeutics, Inc. | Abigail P. Johnson | 4.99M | 9.2% | SCHEDULE 13G/A ↗ |
| Aug 6, 2026 | SCHEDULE 13G/A (amended) | EIKN Eikon Therapeutics, Inc. | FMR LLC | 4.99M | 9.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G | EIKN Eikon Therapeutics, Inc. | Innovation Endeavors ET SPV GP LLC | 147,819 | 0.3% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | EIKN Eikon Therapeutics, Inc. | Innovation Endeavors ET SPV LP | 147,819 | 0.3% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | EIKN Eikon Therapeutics, Inc. | Innovation Endeavors IV GP, LLC | 498,474 | 0.9% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | EIKN Eikon Therapeutics, Inc. | Innovation Endeavors IV LP | 498,474 | 0.9% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | EIKN Eikon Therapeutics, Inc. | Innovation Endeavors III GP, LLC | 2.72M | 5.0% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | EIKN Eikon Therapeutics, Inc. | Innovation Endeavors III LP | 2.72M | 5.0% | SCHEDULE 13G ↗ |
| May 13, 2026 | SCHEDULE 13G | EIKN Eikon Therapeutics, Inc. | Roger M. Perlmutter | 2.89M | 5.2% | SCHEDULE 13G ↗ |
| May 6, 2026 | SCHEDULE 13G | EIKN Eikon Therapeutics, Inc. | Abigail P. Johnson | 3.84M | 7.1% | SCHEDULE 13G ↗ |
| May 6, 2026 | SCHEDULE 13G | EIKN Eikon Therapeutics, Inc. | FMR LLC | 3.84M | 7.1% | SCHEDULE 13G ↗ |
| Apr 29, 2026 | SCHEDULE 13G | EIKN Eikon Therapeutics, Inc. | BlackRock Portfolio Management LLC | 3.00M | 5.5% | SCHEDULE 13G ↗ |
| Feb 18, 2026 | SCHEDULE 13G | EIKN Eikon Therapeutics, Inc. | Platinum Falcon B 2018 RSC Limited | 1.15M | 2.1% | SCHEDULE 13G ↗ |
| Feb 18, 2026 | SCHEDULE 13G | EIKN Eikon Therapeutics, Inc. | Abu Dhabi Investment Authority | 2.82M | 5.2% | SCHEDULE 13G ↗ |
| Feb 12, 2026 | SCHEDULE 13D | EIKN Eikon Therapeutics, Inc. | Peter Svennilson | 6.35M | 11.6% | SCHEDULE 13D ↗ |
| Feb 12, 2026 | SCHEDULE 13D | EIKN Eikon Therapeutics, Inc. | Tim Kutzkey | 6.35M | 11.6% | SCHEDULE 13D ↗ |
| Feb 12, 2026 | SCHEDULE 13D | EIKN Eikon Therapeutics, Inc. | TCG Opportunity III GP, LLC | 1.89M | 3.5% | SCHEDULE 13D ↗ |
| Feb 12, 2026 | SCHEDULE 13D | EIKN Eikon Therapeutics, Inc. | The Column Group Opportunity III GP, LP | 1.89M | 3.5% | SCHEDULE 13D ↗ |
| Feb 12, 2026 | SCHEDULE 13D | EIKN Eikon Therapeutics, Inc. | The Column Group Opportunity III, LP | 1.89M | 3.5% | SCHEDULE 13D ↗ |
| Feb 12, 2026 | SCHEDULE 13D | EIKN Eikon Therapeutics, Inc. | The Column Group IV-A, LP | 148,840 | 0.3% | SCHEDULE 13D ↗ |
| Feb 12, 2026 | SCHEDULE 13D | EIKN Eikon Therapeutics, Inc. | The Column Group IV, LP | 4.31M | 8.0% | SCHEDULE 13D ↗ |
| Feb 12, 2026 | SCHEDULE 13D | EIKN Eikon Therapeutics, Inc. | The Column Group IV GP, LP | 4.46M | 8.3% | SCHEDULE 13D ↗ |
| Feb 11, 2026 | SCHEDULE 13G | EIKN Eikon Therapeutics, Inc. | James B. Tananbaum | 4.15M | 7.7% | SCHEDULE 13G ↗ |
| Feb 11, 2026 | SCHEDULE 13G | EIKN Eikon Therapeutics, Inc. | Foresite Capital VI-A Management, LLC | 408,725 | 0.8% | SCHEDULE 13G ↗ |
| Feb 11, 2026 | SCHEDULE 13G | EIKN Eikon Therapeutics, Inc. | Foresite Capital VI-A, LLC | 408,725 | 0.8% | SCHEDULE 13G ↗ |
| Feb 11, 2026 | SCHEDULE 13G | EIKN Eikon Therapeutics, Inc. | Foresite Capital Opportunity Management V, LLC | 425,852 | 0.8% | SCHEDULE 13G ↗ |
| Feb 11, 2026 | SCHEDULE 13G | EIKN Eikon Therapeutics, Inc. | Foresite Capital Opportunity Fund V, L.P. | 425,852 | 0.8% | SCHEDULE 13G ↗ |
| Feb 11, 2026 | SCHEDULE 13G | EIKN Eikon Therapeutics, Inc. | Foresite Capital Management V, LLC | 1.35M | 2.5% | SCHEDULE 13G ↗ |
| Feb 11, 2026 | SCHEDULE 13G | EIKN Eikon Therapeutics, Inc. | Foresite Capital Fund V, L.P. | 1.35M | 2.5% | SCHEDULE 13G ↗ |
| Feb 11, 2026 | SCHEDULE 13G | EIKN Eikon Therapeutics, Inc. | Foresite Capital Management IV, LLC | 1.96M | 3.6% | SCHEDULE 13G ↗ |
| Feb 11, 2026 | SCHEDULE 13G | EIKN Eikon Therapeutics, Inc. | Foresite Capital Fund IV, L.P. | 1.96M | 3.6% | SCHEDULE 13G ↗ |
35 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 11:24 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances